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Special Report
An International Initiative To Create
a Collaborative for Pharmacovigilance in Hospice
and Palliative Care Clinical Practice
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Abstract
Background:Medication registration currently requires evidence of safety and efficacy from adequately powered
phase 3 studies. Pharmacovigilance (phase 4 studies, postmarketing data, adverse drug reaction reporting)
provide data on more widespread and longer term use. Historically, voluntary reporting systems for pharma-
covigilance have had low reporting rates, relying on ad hoc reporting and retrospective chart reviews, or pro-
spective registries have often been limited to specific drugs or clinical conditions. Furthermore, these data are
often irrelevant in hospice and palliative care due to the timeliness of which such data become available and the
unique characteristics of our population and prescribing: compounding comorbidities, progressive organ failure,
accumulation of symptom-specific medications, tendency to attribute toxicity to disease progression, use of old,
off-patent medications, and incorporation of evolving evidence. There is a need for prospective, systematic
pharmacovigilance in hospice and palliative care.
Method: Here we describe an international, Web-based, 128-bit secure initiative to collect pharmacovigilance
data documenting net clinical benefit and safety of common medications. The intention is for a diverse and large
group of clinical units to record data prospectively on a small deidentified consecutive cohort of patients started
on the medication of interest. A new medication would be studied every 3 months. Three key time points
(different for each medication) will be assessed for each patient, collecting easily codefiable data at baseline, a
point at which clinical benefit should be experienced, and a point at which short- to medium-term toxicities may
occur. Toxicities can additionally be recorded at any time they occur. Data collection will take a maximum of 10
minutes per patient.
Conclusion: The intention is to create an efficient, relevant system to improve hospice and palliative care with
maximally generalizable results.
Introduction
The current registration processes for new medica-tions used by the Therapeutic Goods Administration
(TGA; Australia), Food and Drug Administration (FDA;
United States), European Medicines Evaluation Agency
(EMEA; European Union), and the Pharmaceuticals and
Medical Devices Agency (PMDA; Japan) require evidence of
good manufacturing practice, and short-term safety and effi-
cacy. Understanding the effectiveness of medications in ev-
eryday practice requires additional longer term, real-world,
longitudinal data to complement short-term efficacy data
generated for registration. Once a medication is registered
and widely available, there is a need to track the performance
of that medication in the clinical setting in which it is used,
independently of industry-regulated monitoring.
These same agencies are starting to put a greater emphasis
on longer term outcomes and safety. Globally, regulatory
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agencies are looking toward pharmacovigilance studies to
demonstrate long-term safety and effectiveness. Studies and
efforts contributing towards this goal have many labels, in-
cluding; phase 4, pharmacovigilance, postmarketing surveil-
lance, safetymonitoring, late-phase data, real-world data, and
postregulatory registries. These studies may or may not be in
response to regulatory requirements.
The evidence base for the clinical use of medicines is com-
plex and continually evolving, even for well-established med-
ications in widespread use (most of which are now off-patent).
As treatments change, and the prevalence and combinations
of comorbid illnesses evolve, the relative safety and efficacy
of medicines also change. To provide the evidence base for
evolving clinical care, processes are needed to systematically
monitor and quantify common toxicities, rare effects, long-term
and cumulative effects, and interactions with newmedications
introduced into practice Few registration studies are powered
on safety outcomes. Efficacy or effectiveness are the usual end
points for power calculations. The harm that a medication can
cause is often not detectable due to lack of power because of
event rates, time to events, or the large numbers of random
events collected as safety outcomes in clinical studies.
Current processes for postmarketing surveillance have
substantial limitations. Voluntary pharmacovigilance pro-
grams suffer from low reporting rates in all clinical disciplines
even when events are directly attributable to a drug–host or
drug–drug interactions.1 Industry pharmacovigilance pro-
grammes suffer from being focused on a singlemedication and
the inherent conflicts between the interests of shareholders and
patient safety. Clinical practice databases, such as the UK
General Practice database, are increasingly the source of in-
formation about drug harm, but have inherent limitations as
the data are collected for other purposes and key information
may be missing.2 Data available in the public domain rely on:
1. Ad hoc reporting
2. Retrospective case note audits (i.e., chart reviews): or
3. Prospective audits where there is an agreed systematic
set of data to be recorded (i.e., registries).
Ad hoc reporting of adverse events is inconsistent and rare.
Retrospective chart reviews or local audit is often inconsis-
tently conducted between sites, limiting ability to combine
information to determine large-scale patterns of benefit and
harm. Prospective registries provide great benefit, but his-
torically have been expensive and cumbersome to conduct.
New technologies can help in the latter model either by
more efficient use of existing datasets or through collection
simultaneously across multiple sites. The merging of large
administrative datasets may allow the testing of hypotheses
concerning adverse events.3 Many aggregated datasets for
comparative effectiveness research, including registries and
electronic health record (EHR) data, are now being used to
monitor more systematically for longitudinal drug effective-
ness and safety including adverse event reporting.
In hospice and palliative care, longitudinal pharmacov-
igilance data have not been systematically collected. Clin-
icians and patients may attribute medication-related toxicity
to disease progression, or miss clinically relevant toxicities
simply because they were not actively sought. The culture of
audit and safety reporting is scant, with the use of large scale
administrative datasets and EHRs uncommon. Hospice and
palliative care needs to develop and embed the culture and
approaches for good pharmacovigilance especially given that
symptom-specific medications are added to medications for
long-term comorbid conditions.
A Case for Pharmacovigilance in Hospice
and Palliative Care
Phase 4 pharmacovigilance data directly complement
phase 3 studies. Both elements are needed if the evidence base
for hospice and palliative care practice is to continue to evolve
to improve patient outcomes.4
In hospice and palliative care, the evidence base supporting
application of interventions in clinical practice is complex
and continually evolving. Interventions are diverse, and
frequently coadministered. Medications used are often off-
patent, therefore, manufacturer-sponsored and regulation-
required safety monitoring is unlikely. The population
encountered in palliative care practice is also evolving, with
widening profiles of diseases, multimorbidity, chronicity, and
physiologic changes. Systematic monitoring for commonly
encountered toxicities, rare effects, long-term and cumulative
effects, and interactions with current and new medications as
they become available is rare.
The hospice and palliative care patient population is char-
acterized by increasing frailty, a progressive catabolic state,
varying degrees of progressive organ system impairment, and
the need to add symptom control medications while simulta-
neously managing long-term comorbidities.5 The hospice and
palliative care population is probably the subgroup in clinical
practice at the greatest risk of iatrogenic harm given that this
risk increases greatly with the number of medications.6
There is therefore a need to evaluate repeatedly and sys-
tematically the performance of medications in the target au-
dience for whom they are prescribed. Although, for most
medications the numbers needed to treat (NNT) and to harm
(NNH)may be defined by a pretreatment probability through
clinical trials for short-term scenarios, both parameters re-
quire longer term data beyond a primary efficacy end point.
Furthermore, pretreatment event probability will vary in-
creasingly later in the palliative care disease trajectory. For all
medications, the relationship between NNT and NNH is dy-
namic andwill continue to be adjusted as phase 4 data become
available, and the palliative population and the medications
they are prescribed evolves. NNT and NNH assume a linear
relationship between events and the initiation of therapy,7 but
both parameters will change for individual patients as their
conditions change.
Not only do hospice and palliative care practitioners need
to knowwhen to initiate a medication but constantly updated
evidence to informwhen and how to discontinue medications
is also required.7 Any clinical intervention should have an
evaluable end point with the time to that end point identified
at the time of initiating treatment.8 Likewise, the time course
of major, clinically relevant harms should be ascertainable
from the literature. At their most basic, outcomes will include
predicted benefit being greater than the predicted harm or
vice versa. Medications may be continued or changed by:
 Ceasing the medication;
 Dose reduction;
 Substituting a similar medication that has less adverse
effects; or
 Adding medications to manage the adverse effects.
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Adding medications specifically to manage the side effects
of another medication can potentially lead to ‘‘therapeutic
momentum’’ or a ‘‘prescribing cascade’’ where more and
more medications are added to treat problems from existing
medications.9,10
A key element is to be able to attribute benefits and harms
to a specific medication. Bradford-Hill11 proposed a series of
criteria for assessing causality in populations that has been
adapted to pharmacovigilance. Naranjo et al.12 proposed a
series of theoretical and practical criteria for assessing cau-
sality of harm of medications in individuals including re-
challenge. In practice, severity, scientific plausibility, and the
temporal relationship between a medication starting and an
effect being experienced may be enough to ensure that the
person is not rechallenged with the drug in routine clinical
practice especially in hospice and palliative care. Of the nine
criteria proposed by Naranjo and colleagues to attribute
causality to a medication for an adverse event, five will be
used in the clinical assessment to aid in understanding likely
attribution of a relationship between the medication and the
observed side effect (Table 1). Those that will be omitted are
not realistic for routine use in end-of-life care.
The ability to perform pharmacovigilance studies in hos-
pice and palliative care is becoming more practical. New and
emerging information systems allow the rapid acquisition of
data to inform practice in a way that has not been available
before.13 Multisite collection with minimal impost on clini-
cians and no impost to patients allow a range of specified data
to be collected prospectively to ensure that the evidence base
for safety continues to evolve rapidly.14
A New International Collaborative
Pharmacovigilance Program
The aim of this collaborative program is to systematically
collect data on the clinical benefits and toxicities of medica-
tions used for symptom control in hospice and palliative care
practice at a level that is consistent with and reflective of
contemporary clinical practice, with formalized data collec-
tion embeddedwithin routine care. The intention is to create a
relevant, efficient system to document net clinical benefit and
safety of common medications used in hospice and palliative
care. By creating a simple and internationally accessible sys-
tem, a diverse and large group of clinical units can participate.
A new medication would be studied every 3 months. Three
key time points (different for each medication) will be assessed
for each patient, collecting easily codefiable data at baseline,
a point at which clinical benefit should be experienced, and
a point at which short- to medium-term toxicities may occur
(Fig. 1). Toxicities can additionally be recorded at any time they
occur. Data collection will take a maximum of 10 minutes
per patient. Medication/symptom dyads in the first 12months
Table 1. Adaptation of the Naranjo Criteria to Audit Use in Hospice and Palliative Care
Original Naranjo criteria for attribution
of causality of harm
In the current pharmacovigilance consecutive cohort studies, Naranjo criteria.
. not used (and reason . used
1. Are there previous conclusive
reports on this reaction?
Scored but not recorded by the site.
This will be ascertained once for
each adverse event at the end of
each audit period
2. Did the adverse reaction appear
after the suspected drug was given?
Used
3. Did the adverse reaction improve
when the drug was discontinued
or a specific antagonist was given?
Used
4. Did the adverse reaction appear
when the drug was readministered?
Unethical to do so given that there are
always alternative ways of treating a
symptom
5. Are there alternative causes (other
than the drug) that could on their
own have caused the reaction?
Used
6. Did the reaction reappear when
a placebo was given?
Logistically difficult and ethically
questionable to challenge with
placebo is this clinical setting
7. Was the drug detected in the blood
(or other fluids) in concentrations
known to be toxic?
Logistically difficult to do, and toxic
levels ill-defined for many
medications in this setting
8. Was the reaction more severe when
the dose increased, or less severe
when the dose was decreased?
Unethical to continue a medication and
vary dose if a causal relationship is
strongly suspected given that there
are always alternative ways of
treating a symptom
9. Did the patient have a similar
reaction to the same or similar drug
in any previous exposure?
Used
10. Was the adverse event confirmed
by any objective evidence?
Used
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will include metoclopramide/nausea, haloperidol/delirium,
dexamethasone/appetite, and gabapentin/neuropathic pain.
Specific elements of this pharmacovigilance project include:
 A simple registry format, whereby a consecutive cohort
of people internationally, newly started on the medica-
tion of interest have data collected prospectively against
an agreed pro forma (whether as an inpatient, outpatient
or in the community);
 A series of medication evaluations with a new medica-
tion/symptom dyad commencing every 3 months. (If a
medication has more than one clinical indication, each
indication will be studied at a separate time. For ex-
ample, haloperidol may be used for nausea, delirium
and sedation; each 3-month study would look at only
one clinical indication);
 set time points including:
(i) baseline;
(ii) a single time point at which clinical benefit will be
evaluated; and
(iii) a time point for toxicity assessment.
Ad hoc time points will include withdrawal at any time and
any time the person has toxicity that comes to the attention of
the clinical team and oversight by an audit development
committee with expertise including palliative medicine, clin-
ical pharmacology, and pharmacy.
Data are kept to aminimumwith no identifying information
collected. By choosing a small dataset, the burden on individ-
ual clinicians will also be minimized. For example, although
gender and age will be collected, date of birth will not be col-
lected, ensuring that not only are these deidentified data, they
will also be un-reidentifiable. Comorbidities will be assessed
using the Charlson comorbidity Index15 and functional status
will be assessed using the Australian-modified Karnofsky
Performance Scale.16 Clinical data collected are intended to be
consistent with information that is already collected as a part of
the normal process of prescribing a new medication.
Data will be collected on a 128-bit secure website (www
.caresearch.com.au) that will be customized for each new
dyad of study medication and the specific palliative clinical
indication being studied. This will allow real-time collation of
the data for rapid reporting with the aim that each medica-
tion/indication will be reported in the Journal of Palliative
Medicine.
Since data will be reported external to an organization, and
this program cannot be considered as quality monitoring
only, some notification of human subjects authorities is re-
quired. However, since the data collected are a part of stan-
dard of care, it is anticipated that most hospice and palliative
care programs will be able to participate through a written
waiver from the Research Ethics Committee/Institutional
Review Board or, at worst, as a low-risk application that can
be expedited. Written patient consent should not be required.
Many countries have national authorities or credentialing
bodies that seek demonstration of longitudinal assessment of
practice and quality monitoring as a part of documented best
practice (e.g., Joint Commission in the United States).17 Par-
ticipation in this pharmacovigilance initiative can contribute
to such processes. Also, the data elements can be integrated
































































FIG. 1. Generic representation of time points for the multisite prospective pharmacovigilance data collection.
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quality monitoring (e.g., PCOC, QDACT) or EHRs, and these
data can be transferred to the pharmacovigilance program for
inclusion in rapid reporting of results.13,18
This program will allow a wide range of practices and
practitioners from around the world to participate in this
process allowing rapid updating of information. This will
improve generalizability of findings. The approach is in-
tentionally efficient, inexpensive, and standardized, directly
responding to the problems encountered in wide-scale phar-
macovigilance programs in the past. Individual practitioners
will be able to reflect on their current practice in the light of
toxicities that are specifically sought, with reports requiring
less than 10 minutes to complete. For the discipline, it will
provide another evidence stream to inform net clinical benefit,
not simply a view of who has responded to therapy.
This mechanism provides an exciting opportunity for an
international collaboration to improve clinical practice. Be-
cause of the focus on 3-month time periods, in its current
configuration this surveillance program does not address the
long-term aspects of pharmacovigilance—cumulative effects,
nor long-term toxicity. It will also be limited at this time in its
ability to identify specific drug–drug interactions, but these
are potential future directions if the collaborative is successful.
Conclusion
There is an urgent need to create a network of hospice and
palliative care programmes committed to improving directly
the quality of care that we offer to patients and their families.
By a large number of services committing to collect data
over a 3-month period on a small number of consecutive pa-
tients newly introduced to a new medication for a medica-
tion/indication dyad, a large amount of efficacy and toxicity
data will be available in a way that has not been possible
before in hospice and palliative care. Ultimately, patient-
centered care is about providing patients with sufficient in-
formation as to whether or not they would consider using a
particular therapy.
Any clinical group can join this initiative. Please contact the
corresponding author david.currow@health.sa.gov.au
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